Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell Epitopes recognized in the context of HLA-A*0201

被引:50
作者
Pelte, C
Cherepnev, G
Wang, YJ
Schoenemann, C
Volk, HD
Kern, F
机构
[1] Humboldt Univ, Inst Med Immunol Charite, D-10117 Berlin, Germany
[2] Inst Transfus Med & Immunohamatol, Berlin, Germany
关键词
D O I
10.4049/jimmunol.172.11.6783
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HLA-A2 is the most frequent HLA molecule in Caucasians with HLA-A*0201 representing the most frequent allele; it was also the first human HLA allele for which peptide binding prediction was developed. The Bioinformatics and Molecular Analysis Section of the National Institutes of Health (BIMAS) and the University of Tubingen (Syfpeithi) provide the most popular prediction algorithms of peptide/MHC interaction on the World Wide Web. To test these predictions, HLA-A*0201-binding nine-amino acid peptides were searched by both algorithms in 19 structural CMV proteins. According to Syfpeithi, the top 2% of predicted peptides should contain the naturally presented epitopes in 80% of predictions (www.syfpeithi.de). Because of the high number of predicted peptides, the analysis was limited to 10 randomly chosen proteins. The top 2% of peptides predicted by both algorithms were synthesized corresponding to 261 peptides in total. PBMC from 10 HLA-A*0201-positive and CMV-seropositive healthy blood donors were tested by ex vivo stimulation with all 261 peptides using crossover peptide pools. IFN-gamma production in T cells measured by CFC was used as readout. However, only one peptide was found to be stimulating in one single donor. As a result of this work, we report a potential new T cell target protein, one previously unknown CD8-T cell-stimulating peptide, and an extensive list of CMV-derived potentially strong HLA-A*0201-binding peptides that are not recognized by T cells of HLAA*0201-positive CMV-seropositive donors. We conclude that MHC/peptide binding predictions are helpful for locating epitopes in known target proteins but not necessarily for screening epitopes in proteins not known to be T cell targets.
引用
收藏
页码:6783 / 6789
页数:7
相关论文
共 22 条
[1]   Putative immunodominant human immunodeficiency virus-specific CD8+ T-Cell responses cannot be predicted by major histocompatibility complex class I haplotype [J].
Betts, MR ;
Casazza, JP ;
Patterson, BA ;
Waldrop, S ;
Trigona, W ;
Fu, TM ;
Kern, F ;
Picker, LJ ;
Koup, RA .
JOURNAL OF VIROLOGY, 2000, 74 (19) :9144-9151
[2]   PRESENTATION OF VIRAL-ANTIGEN CONTROLLED BY A GENE IN THE MAJOR HISTOCOMPATIBILITY COMPLEX [J].
CERUNDOLO, V ;
ALEXANDER, J ;
ANDERSON, K ;
LAMB, C ;
CRESSWELL, P ;
MCMICHAEL, A ;
GOTCH, F ;
TOWNSEND, A .
NATURE, 1990, 345 (6274) :449-452
[3]  
CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125
[4]   MOLECULAR-BASIS FOR CYTOLYTIC LYMPHOCYTE-T RECOGNITION OF THE MURINE CYTOMEGALO-VIRUS IMMEDIATE-EARLY PROTEIN-PP89 [J].
DELVAL, M ;
VOLKMER, H ;
ROTHBARD, JB ;
JONJIC, S ;
MESSERLE, M ;
SCHICKEDANZ, J ;
REDDEHASE, MJ ;
KOSZINOWSKI, UH .
JOURNAL OF VIROLOGY, 1988, 62 (11) :3965-3972
[5]   Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection [J].
Diamond, DJ ;
York, J ;
Sun, JY ;
Wright, CL ;
Forman, SJ .
BLOOD, 1997, 90 (05) :1751-1767
[6]   Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers [J].
Elkington, R ;
Walker, S ;
Crough, T ;
Menzies, M ;
Tellam, J ;
Bharadwaj, M ;
Khanna, R .
JOURNAL OF VIROLOGY, 2003, 77 (09) :5226-5240
[7]   SELECTIVE INTERFERENCE WITH CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX PRESENTATION OF THE MAJOR IMMEDIATE-EARLY PROTEIN FOLLOWING INFECTION WITH HUMAN CYTOMEGALOVIRUS [J].
GILBERT, MJ ;
RIDDELL, SR ;
LI, CR ;
GREENBERG, PD .
JOURNAL OF VIROLOGY, 1993, 67 (06) :3461-3469
[8]   Mapping T cell epitopes by flow cytometry [J].
Hoffmeister, B ;
Kiecker, F ;
Tesfa, L ;
Volk, HD ;
Picker, LJ ;
Kern, F .
METHODS, 2003, 29 (03) :270-281
[9]  
Kern F, 2000, EUR J IMMUNOL, V30, P1676, DOI 10.1002/1521-4141(200006)30:6<1676::AID-IMMU1676>3.0.CO
[10]  
2-V